Industry Advisory Council

Chair, Industry Advisory Council
Senior Vice President, Head of Clinical Development
Silverback Therapeutics, Inc.

Samuel C. Blackman, MD, PhD

Samuel Blackman

Samuel Blackman is Senior Vice President and Head of Clinical Development at Silverback Therapeutics in Seattle, Washington. For the past 9 years he has been focused on the early clinical development of novel cancer therapeutics and has held various positions of increasing responsibility within the pharmaceutical industry. Most recently, he served as Senior Medical Director at Juno Therapeutics where he was responsible for clinical development of novel immunotherapies for leukemia, including chimeric antigen receptor (CAR) T cell therapies and high-affinity T cell receptor (TCR) therapies. Previously, Samuel served as Executive Director and Head of Translational Medicine at Seattle Genetics where he was responsible for pre-clinical and early clinical development of novel antibody drug conjugate (ADC) therapeutics for cancer and lead a group of 30 physicians and scientists.

Dr. Walensky is the recipient of numerous awards including a Stand Up to Cancer Innovative Research Grant, an NIH Director’s Transformative RO1 Award, a Burroughs Wellcome Career Award in the Biomedical Sciences, a Leukemia and Lymphoma Society Scholar Award, a Harvard Medical School Young Mentor Award, and most recently, the Dana-Farber Cancer Institute’s Morse Award for Research Excellence, the Samuel Rosenthal Prize for Excellence in Academic Pediatrics, the E. Mead Johnson Award for Pediatric Research, and an NCI Outstanding Investigator R35 Award. He is a member of the American Society for Clinical Investigation, the Society for Pediatric Research, and the American Pediatric Society.

Pin It on Pinterest

Scroll to Top